Nikolaus Krall

Prior to its acquisition by Exscientia, Nikolaus served as the Managing Director of Allcyte, which he had co-founded as a pioneer in AI-driven cancer precision medicine in 2017. Originally trained as an organic chemist at the University of Cambridge, he concluded his doctoral studies at ETH Zurich focusing on the engineering of targeted agents for the treatment of kidney cancer and did a postdoc working on the analysis of drug action in primary human tissues at the CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences in Vienna.